We Have Lost Too Many Legends — but a First-Of-Its-Kind Pill Just Gave Cancer Patients a Chance

America has lost too many legends recently, but there is some good news on the horizon.

Breaking News: The FDA approved a first-of-its-kind pill that could substantially extend the lives of patients with pancreatic cancer. https://t.co/IVgybALGXh
— The New York Times (@nytimes) August 26, 2026

This is amazing news and means so many people will have a chance at a longer life.

Former Sen. Ben Sasse, given 3-4 months to live with Stage 4 pancreatic cancer, credits the experimental RAS inhibitor daraxonrasib (FDA-approved today as Rasonque) for shrinking tumors over 76% and extending his life. Trial nearly doubled survival.https://t.co/bsZemv41sR
— Aftab Khan, MD (@aftab_usa) August 26, 2026

What a time to be alive.

That was fast!

Daraxonrasib-the new wonder drug for pancreatic cancer-is now FDA approved! pic.twitter.com/e7C4M7412D
— Crémieux (@cremieuxrecueil) August 26, 2026

Now, it is available to other patients who could benefit from the drug.

This is the drug former Sen. @BenSasse is on. We discussed with him a few weeks ago:https://t.co/oMIoCH6woB https://t.co/TudjgTffrI
— Jake Tapper 🦅 (@jaketapper) August 26, 2026

This is indeed the drug that has prolonged the life of former Sen. Ben Sasse. It's so good to see him getting this second chance to be with his family and enjoy the people he loves. What a gift.

Yes, Ben Sasse enrolled in a clinical trial of daraxonrasib (now FDA-approved as Rasonque) for his stage 4 metastatic pancreatic cancer. Public updates through late July 2026 show it shrank his tumors over 80%, cut blood cancer markers 99%, reduced pain sharply, and extended his…
— Grok (@grok) August 26, 2026

With big-name doctors like Fauci in the spotlight for so long, it’s pretty easy to see why a lot of people started distrusting the medical establishment. Shifting advice, conflicts of interest, and the whole mess of politics mixed with science left a lot of us with lingering doubts.

That skepticism isn’t a bad thing by itself — questioning authority and asking for real transparency are healthy habits, especially when the stakes are so high. The trick is to keep it productive: stay curious, dig into the actual data, weigh the pros and cons, and don’t just write off every expert or institution.

Because the same system that’s taken some fair hits is still cranking out some amazing progress.

Things like gene therapy, improved mRNA tech, better early cancer detection, and more personalized treatments are moving forward faster than most of us would have imagined ten years ago. If we can acknowledge the flaws and still celebrate the real wins, we get to hold them accountable without missing out on the stuff that genuinely helps people.